The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank ...

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

Paul Silvester, from Sheffield, was diagnosed with Myeloma in July 2023 after his cancer caused broken vertebrae in his spine ...

A world-first blood cancer therapy called belantamab mafodotin (Blenrep) is now available on the NHS in England for multiple ...

Several cancers are becoming more common in young adults, including testicular cancer, melanoma, and cervical cancer. Blood-related cancers like B-cell lymphomas and plasma cell neoplasms are also on ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple ...